BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved April 18, 2026, for 33 new employees totaling 67,247 restricted stock units.

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved April 18, 2026, for 33 new employees totaling 67,247 restricted stock units.

Vesting: 25% vests on May 16, 2027, then one‑twelfth of the remainder quarterly thereafter, subject to continued employment. Awards were granted under the company’s plan adopted November 2019 and amended February 10, 2023 and December 13, 2023.

Argus Apr 22 session

-2.28% close to close Open Argus

Details

News Market Reaction – BBIO

On Apr 22, the day this news came out, BBIO closed 2.28% below the previous close.

Data tracked by StockTitan Argus for the Apr 22 session.

Market Context

This announcement details inducement RSU grants covering 67,247 shares for 33 new employees under Na...

Analysis

This announcement details inducement RSU grants covering 67,247 shares for 33 new employees under Nasdaq Listing Rule 5635(c)(4), with initial vesting on May 16, 2027. It follows a series of material clinical and regulatory milestones in March, including an NDA filing and positive Phase 3 data. Investors following the name may track how ongoing equity-based compensation, insider filings, and future clinical or regulatory updates interact with a share price currently above the 200-day MA and well above the 52-week low.

Key Figures

Share price: $76.195 52-week low distance: 139.83% above low 52-week high distance: 10.3% below high +5 more

Share price

$76.195

Prior close before inducement grant news

52-week low distance

139.83% above low

Vs 52-week low of $31.77

52-week high distance

10.3% below high

Vs 52-week high of $84.94

Volume vs average

0.79x

Today’s volume vs 20-day average

New employee grants

33 employees

Inducement RSU awards approved April 18, 2026

RSU shares granted

67,247 shares

Aggregate inducement RSUs under Nasdaq Rule 5635(c)(4)

Initial vesting date

May 16, 2027

One-fourth of each employee’s RSUs vest

Plan adoption year

2019, amended 2023

Equity Plan adopted Nov 2019; amended Feb 10 and Dec 13, 2023

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Clinical outcomes data

   24h Move

   -0.5%

   Long-term acoramidis data showed large mortality reductions through Month 54.

2. Mar 30

   NDA submission

   24h Move

   -0.5%

   Submitted NDA to FDA for BBP-418 in LGMD2I/R9 based on positive Phase 3 data.

3. Mar 23

   Conference presentation

   24h Move

   +1.6%

   Planned presentation of long-term ATTRibute-CM OLE trial data at ACC meeting.

4. Mar 20

   Inducement grants

   24h Move

   +1.6%

   Inducement RSU awards for 29 new employees under Nasdaq Rule 5635(c)(4).

5. Mar 11

   Phase 3 interim data

   24h Move

   -3.9%

   FORTIFY interim analysis showed rapid, consistent efficacy and favorable safety.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 33 new employees in restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on April 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 33 new employees in restricted stock units for an aggregate of 67,247 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio (BBIO) announce on April 22, 2026 about inducement grants?

BridgeBio announced April 18, 2026 equity inducement grants of 67,247 RSUs to 33 new employees. According to the company, the awards are intended as inducements under Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the existing equity plan.

How do the BridgeBio (BBIO) inducement RSU vesting terms work and when is the first vesting date?

Vesting begins with 25% on May 16, 2027, then one‑twelfth of the remaining shares quarterly. According to the company, all vesting is subject to each employee’s continued employment with BridgeBio or a subsidiary on the applicable vesting dates.

How many employees and how many restricted stock units did BridgeBio (BBIO) grant as inducements?

BridgeBio granted inducement awards to 33 new employees totaling 67,247 restricted stock units. According to the company, the grants were approved April 18, 2026 by the compensation committee under the equity plan.

Under what authority were BridgeBio's (BBIO) inducement awards granted and which plan applies?

The awards were granted as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the company’s equity plan adopted November 2019. According to the company, the plan was amended on February 10, 2023 and December 13, 2023.

Will BridgeBio (BBIO) inducement RSUs dilute existing shareholders materially?

The press release lists 67,247 RSUs granted but gives no outstanding share count, so material dilution cannot be determined from the announcement alone. According to the company, the grants were small‑group inducements under the equity plan but no dilution percentage was disclosed.